Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company.

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

The life-sciences and chemical group said it now expects 2024 net sales in the lower half of its previously expected range of ...

The First Lady, Rebecca Akufo-Addo, has lauded the Merck Foundation for its impactful campaign to break the stigma surrounding infertility in Africa and Asia, citing its "More than a Mother ...

Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...

“Contact dermatitis and stasis dermatitis are often misdiagnosed as cellulitis,” said Merck Manual Professional Version, reviewed by Dr. Wingfield E. Rehmus. A vascular ultrasound scan may be ...

Oct. 23, 2024 (GLOBE NEWSWIRE) -- Modifi Biosciences, Inc. (“Modifi Biosciences”), a leader in the development of direct DNA modification enabled cancer therapeutics, today announced that the company ...

CBSE Class 12 Subject-Wise Lab Manual: The Central Board Of Secondary Education has made available the lab manuals for classes 12 for all the subjects. Students can download the PDFs of these lab ...

Oct 23 (Reuters) - Merck (MRK.N), opens new tab has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm ...

Merck & Co. is putting down $30 million upfront to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset designed to take on the tough-to-treat brain cancer glioblastoma (GBM).